---
layout: default
title: Raloxifene Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 322
evidence_level: L5
indication_count: 0
---

# Raloxifene Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Raloxifene Hydrochloride: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

Raloxifene Hydrochloride is a drug with confirmed DrugBank entry, but the current Evidence Pack contains no original indication records and no TxGNN predicted indications. Due to critical data gaps across all evaluation dimensions, a meaningful repurposing assessment cannot be completed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | No TxGNN predictions generated |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (model prediction not yet available; no supporting studies) |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, no TxGNN predictions have been generated for Raloxifene Hydrochloride in this Evidence Pack. The `predicted_indications` array is empty, and the `inputs_received` field confirms that required input data was not supplied to the pipeline.

Detailed mechanism of action data is not available in this Evidence Pack. Without an original indication, a predicted indication, or MOA data, it is not possible to assess mechanistic plausibility or disease relationship at this time.

To unlock this analysis, the pipeline must first be re-run with complete inputs, including original indication text, DrugBank ID, and package insert data.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Raloxifene Hydrochloride is incomplete — no original indications, no TxGNN predictions, and no safety data are present, making any repurposing evaluation premature.

**To proceed, the following is needed:**

- **Re-run TxGNN pipeline** with Raloxifene Hydrochloride as input to generate predicted indications and confidence scores
- **Retrieve DrugBank ID** to populate mechanism of action (MOA), drug categories, and toxicity data
- **Parse package insert PDF** (source: TFDA official website) to extract approved indications, warnings, and contraindications
- **Verify market status** in the target regulatory jurisdiction (BfArM/Germany) to confirm authorization count and approved indication text
- **Re-query DDI database** once DrugBank ID is confirmed, to populate drug interaction data
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

